Xenon Pharmaceuticals Inc.
General ticker "XENE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.9B (TTM average)
Xenon Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 43.0%.
Estimated limits based on current volatility of 1.9%: low 43.09$, high 44.78$
Factors to consider:
- Total employees count: 327 (+26.3%) as of 2024
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Clinical development risks, Labor/talent shortage/retention, Strategic risks and growth management
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [21.91$, 47.83$]
- 2025-12-31 to 2026-12-31 estimated range: [17.37$, 39.10$]
Financial Metrics affecting the XENE estimates:
- Negative: with PPE of -12.9 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.00 <= 0.33
- Positive: Shareholder equity ratio, % of 94.58 > 63.39
- Positive: Investing cash flow per share per price, % of 5.46 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term XENE quotes
Long-term XENE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $9.43MM | $0.00MM | $0.00MM |
| Operating Expenses | $138.58MM | $214.05MM | $279.30MM |
| Operating Income | $-129.14MM | $-214.05MM | $-279.30MM |
| Non-Operating Income | $3.89MM | $31.37MM | $40.88MM |
| R&D Expense | $105.77MM | $167.51MM | $210.39MM |
| Income(Loss) | $-125.25MM | $-182.69MM | $-238.42MM |
| Taxes | $0.12MM | $-0.29MM | $-4.09MM |
| Profit(Loss)* | $-125.37MM | $-182.39MM | $-234.33MM |
| Stockholders Equity | $721.50MM | $927.92MM | $754.90MM |
| Assets | $754.15MM | $964.80MM | $798.14MM |
| Operating Cash Flow | $-101.03MM | $-151.11MM | $-181.39MM |
| Capital expenditure | $2.89MM | $5.62MM | $3.08MM |
| Investing Cash Flow | $-293.40MM | $-111.39MM | $165.00MM |
| Financing Cash Flow | $278.47MM | $353.52MM | $12.13MM |
| Earnings Per Share** | $-2.07 | $-2.73 | $-3.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.